Kerstin Görlich

1.3k total citations
15 papers, 862 citations indexed

About

Kerstin Görlich is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Kerstin Görlich has authored 15 papers receiving a total of 862 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Hematology, 10 papers in Molecular Biology and 4 papers in Genetics. Recurrent topics in Kerstin Görlich's work include Acute Myeloid Leukemia Research (13 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (3 papers) and Multiple Myeloma Research and Treatments (3 papers). Kerstin Görlich is often cited by papers focused on Acute Myeloid Leukemia Research (13 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (3 papers) and Multiple Myeloma Research and Treatments (3 papers). Kerstin Görlich collaborates with scholars based in Germany, Netherlands and Canada. Kerstin Görlich's co-authors include Arnold Ganser, Michael Heuser, Jürgen Krauter, Oliver G. Ottmann, Gudrun Göhring, Felicitas Thol, Brigitte Schlegelberger, Gerhard Heil, Michael Lübbert and Lothar Kanz and has published in prestigious journals such as Journal of Clinical Oncology, Blood and British Journal of Haematology.

In The Last Decade

Kerstin Görlich

14 papers receiving 847 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kerstin Görlich Germany 11 690 470 289 173 131 15 862
Annika Dufour Germany 14 656 1.0× 414 0.9× 253 0.9× 128 0.7× 154 1.2× 33 843
Marta Pratcorona Spain 14 791 1.1× 572 1.2× 269 0.9× 193 1.1× 214 1.6× 29 1.0k
Jessica Kohlschmidt United States 19 765 1.1× 574 1.2× 239 0.8× 313 1.8× 198 1.5× 50 1.1k
François G. Kavelaars Netherlands 9 429 0.6× 308 0.7× 204 0.7× 161 0.9× 62 0.5× 24 645
Emiliano Fabiani Italy 18 444 0.6× 419 0.9× 184 0.6× 77 0.4× 96 0.7× 48 695
Hans Beier Ommen Denmark 17 940 1.4× 544 1.2× 195 0.7× 163 0.9× 430 3.3× 44 1.1k
Nils Mauritzson Sweden 14 581 0.8× 270 0.6× 244 0.8× 78 0.5× 225 1.7× 18 719
Gerrit‐Jan Schuurhuis Netherlands 12 488 0.7× 267 0.6× 110 0.4× 104 0.6× 154 1.2× 23 693
Judith Neukirchen Germany 13 503 0.7× 190 0.4× 314 1.1× 49 0.3× 52 0.4× 26 659
Kristiina Heinonen Finland 16 714 1.0× 364 0.8× 190 0.7× 74 0.4× 369 2.8× 30 918

Countries citing papers authored by Kerstin Görlich

Since Specialization
Citations

This map shows the geographic impact of Kerstin Görlich's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kerstin Görlich with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kerstin Görlich more than expected).

Fields of papers citing papers by Kerstin Görlich

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kerstin Görlich. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kerstin Görlich. The network helps show where Kerstin Görlich may publish in the future.

Co-authorship network of co-authors of Kerstin Görlich

This figure shows the co-authorship network connecting the top 25 collaborators of Kerstin Görlich. A scholar is included among the top collaborators of Kerstin Görlich based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kerstin Görlich. Kerstin Görlich is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Kloos, Arnold, Robert Geffers, Kerstin Görlich, et al.. (2025). XPO1-dependency of DEK::NUP214 leukemia. Leukemia. 39(5). 1102–1113.
2.
Kloos, Arnold, Christos Georgiadis, Annie Etuk, et al.. (2022). Single and Combinational Multiplex Base-Edited 'Universal' CAR T Cells in a Humanised Model of Primary CD7+CD33+ AML. Blood. 140(Supplement 1). 7425–7426. 4 indexed citations
3.
Chaturvedi, Anuhar, Charu Gupta, Razif Gabdoulline, et al.. (2020). Synergistic activity of IDH1 inhibitor BAY1436032 with azacitidine in IDH1 mutant acute myeloid leukemia. Haematologica. 106(2). 565–573. 27 indexed citations
4.
Chaturvedi, Anuhar, Charu Gupta, Razif Gabdoulline, et al.. (2017). Synergistic Activity of IDH1 Inhibitor Bay-1436032 with Azacitidine in IDH1 Mutant Acute Myeloid Leukemia. Blood. 130. 1352–1352. 8 indexed citations
5.
Chaturvedi, Anuhar, Michelle Cruz, Nidhi Jyotsana, et al.. (2016). Enantiomer-specific and paracrine leukemogenicity of mutant IDH metabolite 2-hydroxyglutarate. Leukemia. 30(8). 1708–1715. 37 indexed citations
6.
Sharma, Amit, Nidhi Jyotsana, Courteney K. Lai, et al.. (2016). Pyrimethamine as a Potent and Selective Inhibitor of Acute Myeloid Leukemia Identified by High-throughput Drug Screening. Current Cancer Drug Targets. 16(9). 818–828. 18 indexed citations
7.
Sharma, Aparna, Nidhi Jyotsana, Anuhar Chaturvedi, et al.. (2016). Pyrimethamine as a Potent and Selective Inhibitor of Acute Myeloid Leukemia Identified by High-throughput Drug Screening.. Current Cancer Drug Targets. 16(9). 818–828. 13 indexed citations
8.
Sharma, Amit, Haiyang Yun, Nidhi Jyotsana, et al.. (2014). Constitutive IRF8 expression inhibits AML by activation of repressed immune response signaling. Leukemia. 29(1). 157–168. 22 indexed citations
9.
Sharma, Amit, Nidhi Jyotsana, Courteney K. Lai, et al.. (2014). High-Throughput Drug Screening Identifies Pyrimethamine As a Potent and Selective Inhibitor of Acute Myeloid Leukemia. Blood. 124(21). 2304–2304. 1 indexed citations
10.
Damm, Frédérik, Katharina Wagner, Kerstin Görlich, et al.. (2012). ID1 expression associates with other molecular markers and is not an independent prognostic factor in cytogenetically normal acute myeloid leukaemia. British Journal of Haematology. 158(2). 208–215. 10 indexed citations
11.
Thol, Felicitas, Sofia Kade, Patrick Löffeld, et al.. (2012). Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. Blood. 119(15). 3578–3584. 318 indexed citations
12.
Wagner, Katharina, Frédérik Damm, Felicitas Thol, et al.. (2011). FLT3-internal tandem duplication and age are the major prognostic factors in patients with relapsed acute myeloid leukemia with normal karyotype. Haematologica. 96(5). 681–686. 39 indexed citations
13.
Damm, Frédérik, Michael Heuser, Michael Morgan, et al.. (2011). Integrative prognostic risk score in acute myeloid leukemia with normal karyotype. Blood. 117(17). 4561–4568. 80 indexed citations
14.
Wagner, Katharina, Frédérik Damm, Gudrun Göhring, et al.. (2010). Impact of IDH1 R132 Mutations and an IDH1 Single Nucleotide Polymorphism in Cytogenetically Normal Acute Myeloid Leukemia: SNP rs11554137 Is an Adverse Prognostic Factor. Journal of Clinical Oncology. 28(14). 2356–2364. 183 indexed citations
15.
Krauter, Jürgen, Kerstin Görlich, Oliver G. Ottmann, et al.. (2003). Prognostic Value of Minimal Residual Disease Quantification by Real-Time Reverse Transcriptase Polymerase Chain Reaction in Patients With Core Binding Factor Leukemias. Journal of Clinical Oncology. 21(23). 4413–4422. 102 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Annika Dufour Breakdown of academic impact, for papers by Marta Pratcorona Breakdown of academic impact, for papers by Jessica Kohlschmidt Breakdown of academic impact, for papers by François G. Kavelaars Breakdown of academic impact, for papers by Emiliano Fabiani Breakdown of academic impact, for papers by Hans Beier Ommen Breakdown of academic impact, for papers by Nils Mauritzson Breakdown of academic impact, for papers by Gerrit‐Jan Schuurhuis Breakdown of academic impact, for papers by Judith Neukirchen Breakdown of academic impact, for papers by Kristiina Heinonen
Rankless by CCL
2026